Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.39 |
| ▸ | USP5 | P45974 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 4/20 | 0.36 |
| ▸ | ACHE | P22303 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28069735 | 0.86 | TDP1 (0.37) | NPC1RAB9ALMNAMAPTSMN1; SMN2 | |
| SCHEMBL30212461 | 0.83 | ACACB (0.42) | NPC1RAB9ALMNAMAPTSMN1; SMN2 | |
| SCHEMBL22296718 | 0.81 | P4HTM (0.34) | NPC1RAB9ALMNAMAPTSMN1; SMN2 | |
| SCHEMBL14553126 | 0.80 | MAPT (0.40) | NPC1RAB9ALMNAMAPTSMN1; SMN2 | |
| SCHEMBL6920475 | 0.79 | P4HTM (0.53) | NPC1RAB9ALMNAMAPTSMN1; SMN2 | |
| SCHEMBL8150961 | 0.79 | NPC1 (0.44) | NPC1RAB9ALMNAMAPTSMN1; SMN2 | |
| SCHEMBL30181544 | 0.79 | P4HTM (0.53) | NPC1RAB9ALMNAMAPTSMN1; SMN2 | |
| SCHEMBL2411829 | 0.78 | GABRA1 (0.49) | NPC1RAB9ALMNAMAPTSMN1; SMN2 | |
| SCHEMBL16472371 | 0.78 | SMN1; SMN2 (0.48) | NPC1RAB9ALMNAMAPTSMN1; SMN2 | |
| SCHEMBL10258367 | 0.78 | HSP90AA1 (0.51) | NPC1RAB9ALMNAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-28 | — | — | US | disclosed |
| US-11802128-B2 | Azetidine and pyrrolidine PARP1 inhibitors and uses thereof | XINTHERA, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230203033-A1 | AZETIDINE AND PYRROLIDINE PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230167131-A1 | HETEROCYCLIC PAD4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230128041-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230128041-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-04-27 | — | — | US | disclosed |
| US-11591331-B2 | PARP1 inhibitors and uses thereof | XINTHERA, INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20130165472-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | PDE4A, PDE4B, PDE5A | NPC1 1428/4885RAB9A 604/4885LMNA 4118/4885 |
| US-11802128-B2 | Azetidine and pyrrolidine PARP1 inhibitors and uses thereof | PARP1, PARP11, PARP12 | NPC1 2929/4885RAB9A 1110/4885LMNA 790/4885 |
| US-20130165472-A1 | HETEROARYLS AND USES THEREOF | PIK3R4, VPS4B, PIK3C2A | NPC1 330/4885RAB9A 109/4885LMNA 3840/4885 |
| US-20230203033-A1 | AZETIDINE AND PYRROLIDINE PARP1 INHIBITORS AND USES THEREOF | PARP1, PARP11, PARP12 | NPC1 3172/4885RAB9A 1205/4885LMNA 1210/4885 |
| US-20230128041-A1 | PARP1 INHIBITORS AND USES THEREOF | PARP1, PARP11, PARP12 | NPC1 2940/4885RAB9A 3330/4885LMNA 316/4885 |
| US-11591331-B2 | PARP1 inhibitors and uses thereof | PARP1, PARP11, PARP12 | NPC1 2940/4885RAB9A 3330/4885LMNA 316/4885 |
| US-20230167131-A1 | HETEROCYCLIC PAD4 INHIBITORS | PADI4, PADI2, PADI6 | NPC1 3595/4885RAB9A 4305/4885LMNA 3053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.